Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINTRAVENOUSStandard

LUMASON

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

Standard Dose
60.7MG/25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview LUMASON is listed in Drugs@FDA under application 203684 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES Form and strength FOR SUSPENSION;INTRAVENOUS - 60.7MG/25MG Sponsor BRACCO Submission history Latest submission status date: 2021-04-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview LUMASON is listed in Drugs@FDA under application 203684 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES Form and strength FOR SUSPENSION;INTRAVENOUS - 60.7MG/25MG Sponsor BRACCO Submission history Latest submission status date: 2021-04-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.